Trending Topic

6 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Grace Johanna Salazar Tamayo

Highlights Determining infection and multidrug resistance (MDR) rates continuously helps to detect the problem to be solved, including outbreaks. Cleaning and disinfection play an important role in preventing MDR and evaluating and correcting the process for better results. MDR control can only be achieved with various measures applied continuously and consistently by a group of […]

10 mins

Peter Hunt, CROI 2022: Advances in HIV Cure with Clinical Perspectives

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Feb 23rd 2022

Despite antiretroviral treatment options becoming widely available, many patients living with HIV still do not have access to treatment. Prof. Peter Hunt (University of California San Francisco, San Francisco, CA, USA) discusses the reasoning behind the need for a HIV cure, comorbidities in an ageing population,  therapeutic targets and clinical strategies that are currently under investigation for a HIV cure and the impact a cure may have on this patient population.

The presentation entitled: ‘Advances in HIV Cure with Clinical Perspectives’  (Abstract #479) was presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2022 (Virtual), 12-16 February 2022.

Questions:

  1. Despite numerous ART options, why is it important to develop a cure for HIV? (0:15)
  2. What therapeutic targets and clinical strategies are currently under investigation for a HIV cure? (2:36)
  3. If a HIV cure can be developed, what impact may it have on patients and society at large? (7:29)

Disclosures: Peter Hunt consults for Viiv Healthcare and Biotron; receives grant support from Gilead; and receives honoraria from Gilead and Viiv Healthcare. 

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of CROI 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup